Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 3/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25599374 | 0.87 | CXCR2 (0.51) | CXCR2 | |
| SCHEMBL25599284 | 0.87 | CXCR2 (0.51) | CXCR2 | |
| SCHEMBL25599361 | 0.85 | NPC1 (0.37) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL25599341 | 0.84 | CXCR2 (0.40) | CXCR2CASP1CASP3CASP7CASP6 | |
| SCHEMBL25599046 | 0.84 | CXCR2 (0.41) | CXCR2 | |
| SCHEMBL25599246 | 0.84 | CXCR2 (0.45) | CXCR2CASP1CASP3CASP7CASP6 | |
| SCHEMBL25599010 | 0.83 | CXCR2 (0.41) | CXCR2CASP1CASP3CASP7CASP6 | |
| SCHEMBL25599566 | 0.82 | CFTR (0.35) | CXCR2CASP1CASP3CASP7CASP6 | |
| SCHEMBL25599278 | 0.82 | CXCR2 (0.39) | CXCR2CASP1CASP3CASP7CASP6 | |
| SCHEMBL25599321 | 0.82 | CXCR2 (0.38) | CXCR2CASP1CASP3CASP7CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | CXCR2 1205/4885PIN1 1245/4885MAPK11 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.